Under certain conditions, bacterial signals set the stage for leukemia

May 16, 2018, University of Chicago Medical Center
A Wright's stained bone marrow aspirate smear from a patient with precursor B-cell acute lymphoblastic leukemia. Credit: VashiDonsk/Wikipedia

A new study by researchers from the University of Chicago Medicine shows that bacterial signals are crucial to the development of a precursor condition to leukemia, which can be induced by disrupting the intestinal barrier or by introducing a bacterial infection.

More than 15 percent of people over the age of 60 develop TET2 (tet methylcytosine dioxygenase 2) mutations in , which give rise to other blood cells. These are known as somatic mutations because they are not inherited, but instead occur by chance with age. These mutations are passed along to the progeny of the mutated cell during cell division and put these patients at risk for blood cancers.

The TET2 mutation gives the hematopoietic stem cells a competitive advantage over others, so they begin to proliferate and make up a greater percentage of cells that become white blood cells. This is a condition known as Clonal Hematopoiesis of Indeterminate Potential, or CHIP. However, the triggers that lead to the progression from CHIP to a precursor condition to leukemia called pre-leukemic myeloproliferation are unknown.

The new study, published May 16, 2018 in Nature, shows that progression from CHIP to pre-leukemic myeloproliferation is dependent on bacterial signals from normally present in the gut that spread to peripheral organs. The authors studied Tet2-deficient mice, which were shown to develop leukemia with age. However, why only a subset of these mice develop leukemia was not understood.

The study demonstrated that loss of TET2 expression leads to defects in the intestinal barrier, allowing bacteria living in the gut to spread into the blood and peripheral organs. The spread of bacteria leads to the release of inflammatory molecules in the blood, which in turn promote the proliferation of hematopoietic stem cells that lack TET2 expression. This sets the stage for pre-leukemic myeloproliferation.

"Years before a patient develops cancer, there are changes happening in the background. They still appear healthy until they reach a tipping point," said Bana Jabri, MD, Ph.D., professor and vice chair for research in the Department of Medicine at UChicago and the senior author of the study. "We have techniques to identify those patients, and now with this paper we know that bacterial signals are key in driving the disease."

A connection to wandering bacteria

Physicians have already developed genetic screening tools to identify patients with CHIP and monitor them, but it is unknown why some go on to develop pre-leukemic myeloproliferation and others do not. The new study suggests that misplaced gut bacteria play a role.

Normally common strains of bacteria, such as Lactobacillus, reside happily in the gut and cannot pass through the intestinal barrier. The research team, led by UChicago postdoctoral scholars Marlies Meisel, Ph.D., and Reinhard Hinterleitner, Ph.D., saw that mice with signs of pre-leukemic myeloproliferation also had gut bacteria that were translocated, or in places they shouldn't be, like the blood and the spleen. These mice also had elevated levels of an inflammatory protein called interleukin-6 (IL-6) produced by immune cells in response to translocated bacteria.

Breakdown of the intestinal barrier can be caused by a severe gastrointestinal infection. In this case, however, there were no pathogens that caused such an infection. Instead, the researchers believe that the TET2 mutations also cause dysfunction in the intestinal barrier, allowing to translocate.

This combination of factors sets the stage for potential leukemia if the cells accumulate more somatic mutations. However, the researchers showed that there may be ways to intervene. Antibiotics and blockade of IL-6 signals reversed the state of pre-leukemic myeloproliferation in mice that developed symptoms. Also, germ-free mice with TET2 mutations did not develop symptoms, further underscoring the requirement that bacteria need to be present to drive the development of leukemia.

Genetic screening can detect TET2 mutations and early signs of changes in hematopoietic stem 10 to 15 years before cancer develops. This means that treatments to block the bacterial signals could reverse pre-leukemic myeloproliferation and limit the risk for developing cancer.

Jabri said the next step is to conduct studies in humans to see if patients with CHIP and pre-leukemic myeloproliferation also have signs of bacterial translocation. Then, clinical trials could test whether treatments that target aberrant IL-6 signals in response to bacteria can reverse its course.

Jabri and hematologist Lucy Godley, MD, Ph.D., professor of medicine at UChicago and another collaborator on the paper, are continuing to study these links between bacterial signals and pre-leukemic myeloproliferation in humans. Combined with increasingly precise genetic screening technology, this could lead to new means of preventing leukemia.

"There would be a whole new set of ways to follow these patients and see if there are signs of bacterial translocation," they said. "Once we see anomalies in the blood we can now think of intervening and reversing it."

Explore further: Vitamin C may encourage blood cancer stem cells to die

More information: Marlies Meisel et al, Microbial signals drive pre-leukaemic myeloproliferation in a Tet2-deficient host, Nature (2018). DOI: 10.1038/s41586-018-0125-z

Related Stories

Vitamin C may encourage blood cancer stem cells to die

August 17, 2017
Vitamin C may "tell" faulty stem cells in the bone marrow to mature and die normally, instead of multiplying to cause blood cancers. This is the finding of a study led by researchers from Perlmutter Cancer Center at NYU Langone ...

Scientists discover vitamin C regulates stem cell function, curbs leukemia development

August 21, 2017
Not much is known about stem cell metabolism, but a new study from the Children's Medical Center Research Institute at UT Southwestern (CRI) has found that stem cells take up unusually high levels of vitamin C, which then ...

Studying a catalyst for blood cancers

April 25, 2017
Imagine this scenario on a highway: A driver starts to make a sudden lane change but realizes his mistake and quickly veers back, too late. Other motorists have already reacted and, in some cases, collide. Meanwhile, the ...

Inhibiting CDK6 prevents leukemic relapse

January 27, 2015
Despite enormous progress in cancer therapy, many patients still relapse because their treatment addresses the symptoms of the disease rather than the cause, the so-called stem cells. Work in the group of Veronika Sexl at ...

Bacterial infection stresses hematopoietic stem cells

August 24, 2017
It has been thought that only immune cells would act as the line of defense during bacterial infection. However, recent research has revealed that hematopoietic stem cells, cells that create all other blood cells throughout ...

Biomarker may predict which formerly treated cancer patients will develop highly fatal form of leukemia

December 3, 2016
Patients successfully treated for breast, colon and other cancers can go on to develop an often-fatal form of leukemia, sometimes years after completion of treatment, due to a genetic mutation leading to secondary malignancies ...

Recommended for you

Pushing closer to a new cancer-fighting strategy

December 11, 2018
A molecular pathway that's frequently mutated in many different forms of cancer becomes active when cells push parts of their membranes outward into bulging protrusions, Johns Hopkins researchers report in a new study. The ...

Scientists have identified and modelled a distinct biology for paediatric AML

December 11, 2018
Scientists have identified and modelled a distinct biology for paediatric acute myeloid leukaemia, one of the major causes of death in children.

HER2 mutations can cause treatment resistance in metastatic ER-positive breast cancer

December 11, 2018
Metastatic breast cancers treated with hormone therapy can become treatment-resistant when they acquire mutations in the human epidermal growth factor receptor 2 (HER2) that were not present in the original tumor, reports ...

Taking uncertainty out of cancer prognosis

December 11, 2018
A cancer diagnosis tells you that you have cancer, but how that cancer will progress is a terrifying uncertainty for most patients. Researchers at Cold Spring Harbor Laboratory (CSHL) have now identified a specific class ...

Loss of two genes drives a deadly form of colorectal cancer, reveals a potential treatment

December 11, 2018
Colorectal cancers arise from earlier growths, called polyps, found on the inner surface of the colon. Scientists are now learning that polyps use two distinct molecular pathways as they progress to cancer, called the "conventional" ...

Successful anti-PD-1 therapy requires interaction between CD8+ T cells and dendritic cells

December 11, 2018
A team led by a Massachusetts General Hospital (MGH) investigator has found that successful cancer immunotherapy targeting the PD-1 molecule requires interaction between cytotoxic CD8+ T cells, which have been considered ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.